MedTrace Logo

ISP-TACE Versus TACE for HCC With PVTT

NCT03108248 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 126

Last updated 2017-04-11

No results posted yet for this study

Summary

For patients with advanced hepatocellular carcinoma (HCC) and portal vein tumor thrombosis (PVTT), the survival benefit of transarterial chemoembolization (TACE) remains modest. This study aimed to investigate whether TACE in combination with irradiation stent placement (ISP) could prolong the survival in patients with HCC and PVTT.

Conditions

  • HCC
  • Portal Vein Tumor Thrombosis

Interventions

DRUG

ethiodized oil; doxorubicin;Gelfoam;

Conventional TACE was performed in both groups as follows. First, multiple angiographies were performed to detect the hepatic arterial anatomy and the possible feeding arteries of tumor, selective catheterization of the artery feeding the tumors was performed. A mixture of ethiodized oil was injected, followed by injection of Gelfoam particles.

DEVICE

stent; idoine-125

In the ISP-TACE group, stent placement was performed one week before TACE. Under fluoroscopic and ultrasonic guidance, the outer stent was firstly placed at the site of the obstructed portal vein, and a self-expandable nitinol stent was immediately followed through a same 10-F sheath.

Sponsors & Collaborators

  • Zhongda Hospital

    lead OTHER

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-01
Primary Completion
2016-12-12
Completion
2017-03-25

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03108248 on ClinicalTrials.gov